In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fujisawa licenses CVT's adenosine receptor agonist

Executive Summary

Fujisawa Healthcare has licensed exclusive North American rights to CV Therapeutics' A2A adenosine receptor agonist CVT-3146, a second-generation cardiac stress agent, as well as a backup compound. The companies will jointly develop CVT-3146 for use in cardiac perfusion imaging, with CVT managing clinical development.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies